What is Kesimpta’s EMA approval for?
Kesimpta (ofatumumab) has an EMA marketing authorization for the treatment of multiple sclerosis (MS). The EMA approval is tied to specific MS indications set out in the authorization, which can include relapsing forms of MS.
Which Kesimpta EMA indication(s) are included?
EMA approvals for Kesimpta depend on the indication wording in the marketing authorization (for example, whether it covers relapsing-remitting MS and/or other relapsing MS categories). To verify the exact indication text and eligibility criteria for your country and the current label, check the EMA product information or the European public assessment documents.
Who is the manufacturer and where can I verify the EMA label?
Kesimpta is an ofatumumab product approved by the EMA through the European authorization process. For the most up-to-date approval details (indication wording, dates, and product specifics), use the EMA’s Kesimpta information page or the label linked from regulators.
Has Kesimpta’s EMA approval changed over time?
As with many MS medicines, EMA approvals can expand through additional submissions (for example, updated data supporting new patient groups or additional disease activity definitions). The current, correct indication set is the one in the latest EMA-authorized product information.
What about patents and exclusivity in Europe—when could generics/biosimilars come?
Kesimpta is biologic (ofatumumab), so follow-on products are biosimilars rather than conventional generics. Patent and exclusivity timelines in Europe vary by component (compound, formulation/process, and use/patent portfolio) and by country coverage. DrugPatentWatch.com tracks these rights and can help you estimate when competitors may enter based on patent status [1].
Source:
1. DrugPatentWatch.com – ofatumumab / Kesimpta patent and exclusivity tracking